Julia J Liu

US Patent:

20200241009, Jul 30, 2020

Filed:

Apr 13, 2020

Appl. No.:

16/847134

Inventors:

- Little Rock AR, US
Julia J. Liu - Little Rock AR, US

International Classification:

G01N 33/68
A61K 31/519
A61K 31/496
A61K 31/427
A61K 31/4245
A61K 31/4035
A61P 1/00
C07K 16/28
C07K 16/24

Abstract:

In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and/or an anti-IL-12/23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and/or and a sphingosine-1-phosphate receptor agonist agent.

US Patent:

20190033326, Jan 31, 2019

Filed:

Feb 2, 2017

Appl. No.:

16/073212

Inventors:

- Little Rock AR, US
Julia J. Liu - Little Rock AR, US

International Classification:

G01N 33/68
A61P 1/00
A61K 31/519
A61K 31/4245
A61K 31/4035
A61K 31/427
A61K 31/496
C07K 16/24
C07K 16/28

Abstract:

In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and/or an anti-IL-12/23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and/or and a sphingosine-1-phosphate receptor agonist agent.